Results 141 to 150 of about 18,139 (185)
Naltrexone-induced skin lesions in a patient with alcohol use disorder.
Ind Psychiatry JRikhari P, Chaubey AN.
europepmc +1 more source
Applicability of the New Zealand-eating behavior questionnaire to predict weight loss responses to naltrexone/bupropion: a proof-of-concept trial. [PDF]
Obes PillarsSchmiedel O +3 more
europepmc +1 more source
Distilling the evidence for GLP-1 receptor agonists in alcohol use disorder. [PDF]
Addict Sci Clin PractBernstein EY, Schacht JP.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2023
Abstract Use of opioid antagonists, particularly when delivered as an extended-release formulation, is a meaningful treatment option for individuals with opioid use disorder who are highly motivated to remain opioid abstinent or do not have access to agonist treatment.
Marina Tsoy-Podosenin, Evgeny Krupitsky
+5 more sources
Abstract Use of opioid antagonists, particularly when delivered as an extended-release formulation, is a meaningful treatment option for individuals with opioid use disorder who are highly motivated to remain opioid abstinent or do not have access to agonist treatment.
Marina Tsoy-Podosenin, Evgeny Krupitsky
+5 more sources
CNS Drugs, 2010
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Sean T, Duggan, Lesley J, Scott
openaire +2 more sources
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Sean T, Duggan, Lesley J, Scott
openaire +2 more sources
Journal of Substance Abuse Treatment, 1985
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +4 more sources
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +4 more sources